XRCC1基因多态与晚期胃癌化疗敏感性的关系  

Relationship between polymorphisms of XRCC1 gene and sensitivity to chemotherapy in advanced gastric cancer

作　　者：高长明[1] 陈环球[1] 陆建伟[1] 丁建华[1] 李苏平[1] 吴建中[1] 曹海霞[1] 冯继锋[1] 

机构地区：[1]江苏省肿瘤防治研究所.江苏省肿瘤医院,南京市210009

出　　处：《临床合理用药杂志》2010年第19期4-6,共3页Chinese Journal of Clinical Rational Drug Use

基　　金：江苏省科技厅社会发展重点项目(No:BS2007010)

摘　　要：目的观察DNA修复酶XRCC1基因密码子399和194多态与晚期胃癌患者对5-氟尿嘧啶(5-FU)和铂类药物化敏感性的关系。方法 91例晚期胃癌患者给予5-FU和铂类药物方案治疗,化疗前检测XRCC1基因型。观察化疗疗效及其与XRCC1基因多态性的关系。结果本组化疗有效率为37.4%。XRCC1399和XRCC11943种基因型化疗有效率比较差异均无统计学意义(P>0.05)。XRCC1399杂合子Arg/Gln基因型骨髓抑制发生率为25.7%低于纯合子基因型(Gln/Gln和Arg/Arg)的50.0%和47.8%;XRCC1399Gln等位基因携带型(Gln/Gln和Arg/Gln)呕吐反应发生率为30.0%和31.4%低于Arg/Arg基因型的54.4%;XRCC1194Trp/Trp基因型骨髓抑制发生率为0低于Arg等位基因携带型(Arg/Trp和Arg/Arg)的41.5%和45.2%,差异均有统计学意义(P<0.05)。结论 XRCC1基因多态性与晚期胃癌患者对5-FU为基础的含铂类药物方案化疗疗效的关系不确切,但与晚期胃癌对5-FU和铂类药物化疗的Ⅱ度以上严重不良反应发生有关,检测XRCC1基因型可以为晚期胃癌化疗药物的选择、避免严重毒副反应的发生提供参考依据。Objective To investigate the relationship between polymorphisms of DNA repair gene XRCC1 and sensitivity to fluoropymidine（5-FU）/platin-based chemotherapy in advanced gastric cancer.Methods 91 cases were treated with 5-FU/platin-based chemotherapy,and the XRCC1 gene type was detected before therapy.Observed the chemotherapy effect and its relationship with polymorphisms of XRCC1 gene.Results The chemotherapy effective rate of the whole group was 37.4%.There were no significant differences among different types of XRCC1 399 genes or XRCC1 194 genes（P〉0.05）.The incidence rate of myelo-suppression of the XRCC1 399 Arg/Gln genetype was 25.7% lower than 50.0% and 47.8% of the Arg/Arg and Gln/Gln genotype;The incidence rate of vomiting of the XRCC1 399 Gln allele was 30.0% and 31.4% lower than 54.4% of the Arg/Arg genotype;The incidence rate of myelo-suppression of the XRCC1 194 Trp/Trp genetype was 0 lower than 41.5% and 45.2% of the Arg/Trp and Arg/Arg genotype.All the differences above were statistically significant（P〈0.05）.Conclusion It is not sure about the relationship between polymorphisms of XRCC1 gene and sensitivity to fluoropymidine（5-FU）/platin-based chemotherapy in advanced gastric cancer,but the polymorphisms of XRCC1 gene has something to do with severe adverse events to 5-FU/platin-based chemotherapy,suggesting that XRCC1 genotypes can be used as reference for chosing chemotherapy agents and avoiding severe adverse events.

关 键 词：XRCC1 基因多态性 胃癌 晚期 化疗 

分 类 号：R735.2[医药卫生—肿瘤]